M-SRG
Nomenclature
SD-Rag2em1SmocIl2rgem1Smoc
Cat. NO.
NR-KO-210360
Strain State
Repository Live
Gene Summary
Gene Symbol
Model Description
Validation Data
Fig1. Complete deletion of T, B and NK cells of M-SRG rats. Spleen and peripheral blood cells from SD and M-SRG rats were collected to analyze their compositions of T, B and NK cells by FACS.
Fig2. Subcutaneous xenograft tumor growth of HT29 cells in M-SRG rats. Human colorectal adenocarcinoma cell line HT-29 (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig3. Subcutaneous xenograft tumor growth of PC-3 cells in M-SRG rats. Human prostatic adenocarcinoma cell line PC-3 (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig4. Subcutaneous xenograft tumor growth of LNCaP clone FGC cells in M-SRG rats. Human metastatic prostate carcinoma cell line LNCaP clone FGC (2x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig5. Subcutaneous xenograft tumor growth of A2780 cells in M-SRG rats. Human ovarian cancer cell line HT-29 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig6. Subcutaneous xenograft tumor growth of MV4-11 cells in M-SRG rats. Human monocytic leukemia cell line MV4-11 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A)Tumor volume. (B) Body weight change.
Fig7. Subcutaneous xenograft tumor growth of OCI-AML-3 cells in M-SRG rats. Human acute myeloid leukemia cell line OCI-AML-3 (1x107) were mixed with Matrigel and inoculated subcutaneously into M-SRG rats (n=6). (A) Tumor volume. (B) Body weight change.
Fig8. Blood Routine Tests in M-SRG rats.
Fig9. Blood biochemistry in M-SRG rats.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreOur vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more
